Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, Johnston J, Low J, Ybarra R, Slaga D, Yang J, Ovacik M, Dybdal NO, Totpal K, Junttila MR, Ellerman D, Lee G, Dennis MS, Prell R, Junttila TT.
Staflin K, et al. Among authors: low j.
JCI Insight. 2020 Apr 9;5(7):e133757. doi: 10.1172/jci.insight.133757.
JCI Insight. 2020.
PMID: 32271166
Free PMC article.